Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

by | Mar 11, 2026 | Clinical Trials | 0 comments

​ Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Ficerafusp alfa; Drug: Pembrolizumab

Sponsors: Dana-Farber Cancer Institute; Bicara Therapeutics

Not yet recruiting Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Ficerafusp alfa; Drug: Pembrolizumab
Sponsors: Dana-Farber Cancer Institute; Bicara Therapeutics
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *